Lack of prognostic significance of CD34 expression in adult AML when FAB M0 and M3 are excluded [10]

American Journal of Hematology

Volumn 57, Issue 3, 1998, Pages 265-266

  Kyoda, K ^a   Nakamura, S ^a   Hattori, N ^a   Takeshima, M ^a   Nakamura, K ^a   Kaya, H ^a   Matano, S ^a   Okumura, H ^a   Kanno, M ^a   Ohtake, S ^a   Matsuda, T ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; DAUNORUBICIN; ENOCITABINE; ETOPOSIDE; MERCAPTOPURINE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; HUMAN; IMMUNOPHENOTYPING; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR CLASSIFICATION;

ADULT; ANTIGENS, CD34; DISEASE PROGRESSION; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LEUKEMIA, MYELOCYTIC, ACUTE; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0031931898     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199803)57:3<265::AID-AJH24>3.0.CO;2-8     Document Type: Letter

References (5)